Eyegate Pharmaceuticals, Inc. (EYEG) Given Buy Rating at HC Wainwright

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Wednesday.

Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at $1.07 on Wednesday. Eyegate Pharmaceuticals has a 12 month low of $0.90 and a 12 month high of $3.90.

COPYRIGHT VIOLATION NOTICE: “Eyegate Pharmaceuticals, Inc. (EYEG) Given Buy Rating at HC Wainwright” was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/11/15/eyegate-pharmaceuticals-inc-eyeg-given-buy-rating-at-hc-wainwright.html.

A hedge fund recently raised its stake in Eyegate Pharmaceuticals stock. Vanguard Group Inc. grew its holdings in shares of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 247,319 shares of the specialty pharmaceutical company’s stock after buying an additional 1,988 shares during the period. Vanguard Group Inc. owned 2.27% of Eyegate Pharmaceuticals worth $339,000 as of its most recent SEC filing. 13.05% of the stock is currently owned by hedge funds and other institutional investors.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply